Baxdrostat: A New Drug for Resistant High Blood Pressure Treatment
Resistant high blood pressure affects millions worldwide and often remains uncontrolled even with multiple medications. A new drug, baxdrostat, has shown promise as an effective treatment option for patients who fail to respond to standard therapies.
What Is Resistant High Blood Pressure?
Doctors define resistant high blood pressure as a condition where systolic and diastolic readings remain above 130/80 mm Hg despite taking two or more medications. This condition, often linked to high aldosterone levels, increases risks of stroke, heart attack, and kidney damage. Baxdrostat works by lowering aldosterone, preventing fluid retention and reducing blood pressure.
Clinical Trial Results of Baxdrostat
A Phase III trial followed nearly 800 patients with resistant hypertension for 12 weeks. Their average blood pressure at the start was 149/87 mm Hg. Patients taking baxdrostat (1–2 mg daily) alongside existing medications saw their systolic pressure drop by 9–10 mm Hg more than those on placebo.
A smaller substudy also showed a 15 mm Hg reduction in 24-hour readings, with no major side effects. Around 40% of patients reached healthy systolic levels below 130 mm Hg compared with 19% in the placebo group.
Benefits Over Standard Treatments
Current medications like spironolactone can cause side effects, including hormone-related issues. Baxdrostat appears safer, with fewer problems such as breast tenderness, sexual dysfunction, or menstrual irregularities. Researchers also noted mild potassium increases and kidney effects that may even be protective.
Long-Term Effectiveness
The trial included an eight-week withdrawal phase. Patients who continued baxdrostat saw further drops, while those who stopped treatment had pressure rebound. This lasting effect makes the drug unique compared to other classes used for resistant high blood pressure.
Expert Opinions
Cardiologists say the results are impressive and meaningful for patients struggling with uncontrolled hypertension. Baxdrostat’s ability to sustain reductions could lower long-term risks of heart disease, stroke, and heart failure.
The Future of Baxdrostat for Resistant High Blood Pressure
AstraZeneca, the drug’s developer, plans to seek FDA approval by late 2025. Experts stress that baxdrostat should complement lifestyle changes, regular monitoring, and comprehensive care. While further studies are needed, this treatment may soon become an essential tool in managing resistant high blood pressure.
Raed: Ordinary Ice Electricity: A Surprising Scientific Discovery.
